CellGEN Therapies produces advanced gene-, cell- and tissue-therapeutic products (ATMPs) for early phase clinical trials according to good manufacturing principles (GMP).

We focus on the development and production of small batches of ATMPs or RNA vaccines as required for personalized medicines or phase I studies. In this way, we preferentially interact with academic researchers as well as companies that have developed personalized ATMPs.

We help UZ Gent, external clients and partners to move their research “from bench to bedside” by providing the right expertise, equipment and a licensed facility for the production of small batches of cell and gene therapeutics.

About the GMP Unit

CellGENTherapies was founded in 2014. In 2016 the first ATMP was produced under GMP conditions. Ever since, the activity has been growing and other technologies became part of the portfolio. CellGENTherapies is currently licensed for the production of investigational advanced therapy medicinal products and will apply in 2024 for a license for the production of microbial vaccines. 

To house the expanding activities, a new GMP unit will be constructed on the site of UZ Gent (Ghent University Hospital) and should be fully operational by mid 2025.

Our location on the campus of Ghent University Hospital ensures synergies with both the hospital and Ghent University. It also benefits from Ghent’s reputation as a leading cluster for biotech and medical companies, and its position as a gateway to Europe and the world.

Get in touch

Good Manufacturing Principles or GMP is a strict, tightly controlled framework with which a building and processes must comply. At the heart of the GMP is a sterile clean room with highly qualified persons that execute processes following strict guidelines. This is ensured by regular audits by the FAMHP.


Dendritic cells

lipid nano-particles

In-vitro transcribed RNA

Stromal vascular fraction (SVF)

Multivirus-specific T-cells

Point-of-care CAR-T cells (starting 2024)


Technology transfer

We start from your research protocols and translate them towards GMP-compliant protocols. Additionally, Ghent University licenses technology in the field of gene and cell therapy.

Writing of IMPDs

We write investigational medicinal product dossiers and interact with the regulatory body.

Quality testing

We have our own in-house quality laboratory and additionally work with recognized external analytical service providers.

Latest News


Bart Vandekerckhove

Head of the unit

Joline Ingels

Production unit

Saskia De Smet

Production unit

Viviane Van de Steene

Production unit

Bo Coppens

Production unit

Stijn De Munter

Production unit

Valerie Redant

Production unit

Nele Lootens

Quality assurance unit

Eva Van Houtte

Quality assurance unit

Ryma Addoun

Quality assurance unit

Louise De la Mane

Qualified person

Tim Desmet

Business development